Evidence map›Paper›PMID 27730172›Full record

ArticleERJ open research2016

Genetic regulation of expression of leukotriene A4 hydrolase.

Tomasz Szul, Peter Castaldi, Michael H Cho, J Edwin Blalock, Amit Gaggar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Tomasz SzulDept of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Program in Protease and Matrix Biology, University of Alabama at Birmingham, Birmingham, AL, USA; Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL, USA; Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Peter CastaldiChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Michael H ChoChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, USA.
J Edwin BlalockDept of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Program in Protease and Matrix Biology, University of Alabama at Birmingham, Birmingham, AL, USA; Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL, USA; Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Amit GaggarDept of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Program in Protease and Matrix Biology, University of Alabama at Birmingham, Birmingham, AL, USA; Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL, USA; Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, USA; Medicine Service, United States Department of Veterans Affairs Medical Center, University of Alabama at Birmingham, Birmingham, AL, USA.
University of Alabama at Birmingham · USBrigham and Women's Hospital · US

Funding

MECHANISMS OF HYPERTENSION AND CARDIOVASCULAR DISEASEST32HL007457 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Martin E Young · 1985 to 2026
$8.6M
Using Integrative Genomics To Identify and Characterize Emphysema-Associated eQTLR01HL124233 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI CASTALDI, PETER · 2014 to 2024
$7.1M
A Novel Proteolytic System of Pulmonary InflammationR01HL102371 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GAGGAR, AMIT · 2010 to 2021
$3.3M
Genetics of Smoke-Altered LTA4H in COPDR01HL126596 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BLALOCK, J EDWIN, CASTALDI, PETER · 2015 to 2018
$1.6M
Effect of Macrolide Treatment on a Novel Pathway of Neutrophilic Inflammation inR01HL090999 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BLALOCK, J EDWIN · 2007 to 2010
$1.5M
PGP, A Possible Biomarker for COPD Exacerbations and or ProgressionR01HL114439 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BLALOCK, J EDWIN · 2012 to 2015
$1.5M
Therapeutics for Chronic Lung Diseases: Antagonists of PGP, Chemokines and CXCRR01HL087824 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BLALOCK, J EDWIN · 2009 to 2010
$823k
Predictive Modeling with Clinical and Genomic Data in COPDK08HL102265 · NHLBI · TUFTS MEDICAL CENTER · PI CASTALDI, PETER · 2010 to 2014
$641k
APPROACHES TO IDENTIFY RARE AND COMMON GENETIC DETERMINANTS IN SEVERE COPDK08HL097029 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI CHO, MICHAEL H. · 2010 to 2013
$548k
Prolyl Endopeptidase-Mediated Matrix Remodeling and Inflammation in COPDI01BX001756 · VA · BIRMINGHAM VA MEDICAL CENTER · PI GAGGAR, AMIT · 2015 to 2018
–
BLRD VA I01 BX001756NHLBI NIH HHS K08 HL097029NHLBI NIH HHS K08 HL102265NHLBI NIH HHS R01 HL087824NHLBI NIH HHS R01 HL090999NHLBI NIH HHS R01 HL102371NHLBI NIH HHS R01 HL114439NHLBI NIH HHS R01 HL124233NHLBI NIH HHS R01 HL126596NHLBI NIH HHS T32 HL007457
6 · The paper itself

Abstract

In chronic inflammatory lung disorders such as chronic obstructive pulmonary disease (COPD), the concurrent organ-specific and systemic inflammatory responses lead to airway remodelling and vascular dysfunction. Although a major common risk factor for COPD, cigarette smoke alone cannot explain the progression of this disease; there is increasing evidence that genetic predisposition also plays a role in COPD susceptibility and progression. A key enzyme in chronic lung inflammation is leukotriene A4 hydrolase (LTA4H). With its aminopeptidase activity, LTA4H degrades the neutrophil chemoattractant tripeptide PGP. In this study, we used the luciferase reporter gene analysis system and quantitative trait locus analysis to explore the impact of single-nucleotide polymorphisms (SNPs) in the putative promoter region of

Identifiers

PMID27730172
PMCPMC5005155
OpenAlexW2291523384

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.